ImmunoCellular Therapeutics is developing dendritic cell (DC)-based therapies for the treatment of brain cancer and other tumors. The lead product candidate, ICT-107, targets multiple tumor-associated antigens for newly diagnosed glioblastoma, the most common and lethal type of brain cancer. The pipeline also includes ICT-121, which targets the CD133 stem cell antigen in recurrent glioblastoma, ICT-140, which targets stem cell-associated antigens in ovarian cancer, and the Stem-to-T-Cell program which engineers the patient’s hematopoietic stem cells to generate antigen-specific cancer-killing T cells.

Copyright 2017 by Immunocellular Therapeutics, Ltd.
All Rights Reserved